Therapy of HPV 16-associated carcinoma with dendritic cell-based vaccines: In vitro priming of the effector cell responses by DC pulsed with tumour lysates and synthetic RAHYNIVTF peptide

0191136 - UMG-J 20000242 RIV GR eng J - Článek v odborném periodiku
Indrová, Marie - Bubeník, Jan - Šímová, Jana - Vonka, V. - Němečková, Š. - Mendoza, Luis - Reiniš, Milan
Therapy of HPV 16-associated carcinoma with dendritic cell-based vaccines: In vitro priming of the effector cell responses by DC pulsed with tumour lysates and synthetic RAHYNIVTF peptide.
International Journal of Molecular Medicine. Roč. 7, č. 1 (2001), s. 97-100. ISSN 1107-3756. E-ISSN 1791-244X
Grant CEP: GA MZd NC5526; GA MZd NC4501; GA ČR GA312/98/0826; GA ČR GA312/99/0542; GA ČR GA301/00/0114; GA AV ČR IAA7052002
Výzkumný záměr: CEZ:AV0Z5052915
Kód oboru RIV: FD - Onkologie a hematologie
Impakt faktor: 1.689, rok: 2001

Murine carcinoma induced by MK 16 cells expressing HPV 16 E6/E7 oncogenes was utilized to examine the therapeutic effects of dendritic cell-based tumour vaccines. Mice carrying MK 16 tumours were injected with DC or DC pulsed with MK 16 tumour lysate. Both vaccines inhibited growth of MK 16 transplants, the pulsed DC being more efficient. DC vaccines pulsed with HPV 16 thus seem to be a prospective modality for treatment of HPV16-associated carcinoma.
Trvalý link: http://hdl.handle.net/11104/0086893